Work

Effectiveness and safety of ipilimumab therapy in advanced melanoma: evidence from clinical practice sites in the US

Year: 2015

Type: article

Abstract: he incidence of melanoma, the most serious form of skin cancer, is rising globally.1,2 Although most patients are diagnosed and treated at an early stage of the disease and have a good prognosis, survival among patients with unresectable or metastatic (advanced) melanoma remains poor.In the United States, an estimated 9,940 deaths from melanoma will occur in 2015; 1 in Europe, melanoma accounts for an estimated 20,000 deaths annually.2 Patients with advanced melanoma historically had a dismal prognosis, with median survival of less than a year.3,4 In a meta-analysis of 2,100 patients with advanced melanoma from 42 phase 2 cooperative group clinical trials with accrual closing between 1975 and 2005, the median overall survival (OS) was 6.2 months (95% confdence interval [CI], 5.9-6.5), with 25.5% (95% CI, 23.6-27.4)alive at 1 year.3 Another recent systematic review estimated median OS for stage IV melanoma of about 8 months,

Source: The Journal of Community and Supportive Oncology

DOI: 10.12788/jcso.0124